Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Sees Emerging Market Opportunity for Forest Anti-Infective

This article was originally published in PharmAsia News

Executive Summary

In years gone by, practically no Big Pharma would have signed a licensing deal that did not include U.S. rights. These days, however, the rise of China, India and other emerging markets is providing more geographic carve-out opportunities for deal-makers

You may also be interested in...



J&J, GSK, AstraZeneca's Emerging Markets Roundup: PharmAsia News Earnings Call Roundup

Quarterly earnings calls seem lacking these days unless a company references its plans for emerging markets. PharmAsia News combs through quarterly earnings reports to spot developing trends in emerging market strategies.

J&J, GSK, AstraZeneca's Emerging Markets Roundup: PharmAsia News Earnings Call Roundup

Quarterly earnings calls seem lacking these days unless a company references its plans for emerging markets. PharmAsia News combs through quarterly earnings reports to spot developing trends in emerging market strategies.

Basilea Takes On Partner J&J In Arbitration Claim Over Ceftobiprole Delays

In an era where most product- and innovation-hungry big pharma firms have been desperately promoting themselves as "best partners," it is perhaps easy to forget what can go wrong when a biotech entrusts its asset to a larger firm

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel